Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Weighted Average) (2020 - 2025)

Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $160.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.3% year-over-year to $160.4 million, compared with a TTM value of $160.4 million through Dec 2025, up 9.3%, and an annual FY2025 reading of $160.4 million, up 9.3% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $160.4 million at Xeris Biopharma Holdings, up from $158.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $160.4 million in Q4 2025, with the low at $40292.0 in Q2 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $100.2 million, with a median of $135.8 million recorded in 2022.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 155159.11% in 2024 and then plummeted 99.97% in 2025.
  • Tracing XERS's Shares Outstanding (Weighted Average) over 5 years: stood at $79.0 million in 2021, then surged by 71.62% to $135.6 million in 2022, then rose by 1.51% to $137.7 million in 2023, then grew by 6.61% to $146.8 million in 2024, then increased by 9.3% to $160.4 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Shares Outstanding (Weighted Average) are $160.4 million (Q4 2025), $158.6 million (Q3 2025), and $40292.0 (Q2 2025).